Does Rallies show Form 4 insider transactions for LIXT?

Yes. Rallies tracks LIXT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LIXT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LIXT. It does not provide personalized investment advice.

LIXT (Lixte Biotechnology Holdings, Inc. Common Stock) Stock Analysis - Insider Trades

Lixte Biotechnology Holdings, Inc. Common Stock (LIXT) is a publicly traded Healthcare sector company. As of May 21, 2026, LIXT trades at $5.60 with a market cap of $54.60M and a P/E ratio of 0.00. LIXT moved +1.90% today. Year to date, LIXT is +48.15%; over the trailing twelve months it is +327.48%. Its 52-week range spans $0.64 to $6.26. Rallies surfaces LIXT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LIXT stock inside the company?

Recent LIXT insider activity includes Bernards Rene bought 5.53K, van der Baan Bastiaan Jeroen bought 10.00K, Bernards Rene bought 5.53K, Bernards Rene bought 4.47K, and Bernards Rene bought 4.47K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LIXT Key Metrics

Key financial metrics for LIXT
Metric	Value
Price	$5.60
Market Cap	$54.60M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$6.26
52-Week Low	$0.64
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-6.01M
Gross Margin	0.00%

Recent LIXT Insider Trades

Bernards Rene bought 5.53K (~$13.87K) on Oct 3, 2023.
van der Baan Bastiaan Jeroen bought 10.00K (~$28.00K) on Oct 3, 2023.
Bernards Rene bought 5.53K (~$13.87K) on Oct 3, 2023.
Bernards Rene bought 4.47K (~$10.24K) on Oct 2, 2023.
Bernards Rene bought 4.47K (~$10.24K) on Oct 2, 2023.

Latest LIXT News

LIXTE Files Q1 10-Q, Expands Ovarian Cancer Study with GSK’s Dostarlimab — May 14, 2026
LIXTE Advances LB-100 PP2A Inhibitor into Clinical Trials for Ovarian and Colon Cancer — Apr 27, 2026
LIXTE Biotechnology Sees 40% Disease Control Rate in Ovarian Cancer Trial — Apr 13, 2026
Lixte Expands LB-100 Clinical Trials, Partners with Liora Technologies to Boost Cancer Therapy — Apr 10, 2026
LIXTE Advances Cancer Therapy with World’s Only Clinical-Stage PP2A Inhibitor — Apr 1, 2026

LIXT Analyst Consensus

LIXT analyst coverage data. Average price target: $0.00.

Common questions about LIXT

Who is trading LIXT stock inside the company?: Recent LIXT insider activity includes Bernards Rene bought 5.53K, van der Baan Bastiaan Jeroen bought 10.00K, Bernards Rene bought 5.53K, Bernards Rene bought 4.47K, and Bernards Rene bought 4.47K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LIXT?: Yes. Rallies tracks LIXT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LIXT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LIXT. It does not provide personalized investment advice.